The use of combination therapy in pulmonary arterial hypertension: new developments
Key result
Combination therapy using bosentan with prostanoids or PDE-5 inhibitors improves exercise capacity in patients with pulmonary arterial hypertension compared with placebo.
Why the study?
Does combination therapy improve exercise capacity and long-term outcomes in patients with pulmonary arterial hypertension?
Population
Patients with pulmonary arterial hypertension (PAH)
Comparison
Combination therapy (e.g., bosentan in… vs Placebo or monotherapy
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support bosentan combinations for exercise capacity in PAH; leaves open long-term outcome benefits and optimal regimens.
Structured PICO
Does combination therapy improve exercise capacity and long-term outcomes in patients with pulmonary arterial hypertension?
P
Population
Patients with pulmonary arterial hypertension (PAH)
I
Intervention
Combination therapy (e.g., bosentan in combination with prostanoids and phosphodiesterase (PDE)-5 inhibitors, or PDE-5 inhibitors in combination with prostanoids)
C
Comparator
Placebo or monotherapy
O
Outcome
Exercise capacitysurrogate
Combination therapy in pulmonary arterial hypertension appears to improve exercise capacity and may provide acceptable long-term results in advanced disease.
Limitations
- The appropriate timing of combination therapy requires further evaluation
Cite This Study
Galiè et al. (2009) conducted a review in Pulmonary arterial hypertension (PAH). Combination therapy (e.g., bosentan with prostanoids and PDE-5 inhibitors) vs. Placebo was evaluated on Exercise capacity. Combination therapy using bosentan with prostanoids or PDE-5 inhibitors improves exercise capacity in patients with pulmonary arterial hypertension compared with placebo.